1. Home
  2. HOTH vs NCEL Comparison

HOTH vs NCEL Comparison

Compare HOTH & NCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Hoth Therapeutics Inc.

HOTH

Hoth Therapeutics Inc.

HOLD

Current Price

$1.03

Market Cap

17.7M

Sector

Health Care

ML Signal

HOLD

NCEL

NewcelX Ltd. Ordinary Shares

N/A

Current Price

$2.80

Market Cap

13.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
HOTH
NCEL
Founded
2017
2008
Country
United States
Switzerland
Employees
N/A
11
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
17.7M
13.2M
IPO Year
2018
N/A

Fundamental Metrics

Financial Performance
Metric
HOTH
NCEL
Price
$1.03
$2.80
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$5.00
N/A
AVG Volume (30 Days)
407.5K
19.3K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.66
$1.89
52 Week High
$2.12
$4.70

Technical Indicators

Market Signals
Indicator
HOTH
NCEL
Relative Strength Index (RSI) 51.17 52.39
Support Level $0.99 $2.63
Resistance Level $1.12 $3.19
Average True Range (ATR) 0.07 0.16
MACD 0.01 -0.01
Stochastic Oscillator 21.64 47.17

Price Performance

Historical Comparison
HOTH
NCEL

About HOTH Hoth Therapeutics Inc.

Hoth Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing new-generation therapies for unmet medical needs. It is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT); and a treatment and/or prevention for Alzheimer's or other neuroinflammatory diseases (HT-ALZ). The company also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004); and an obesity treatment, and obesity-related diseases and conditions (HT-VA).

About NCEL NewcelX Ltd. Ordinary Shares

NewcelX Ltd is a biotechnology company developing transformative cell-based and small-molecule therapies for neurodegenerative and metabolic diseases. The company's integrated platform combines advanced stem-cell technologies and neuroscience expertise to deliver scalable, regenerative treatments targeting conditions such as Amyotrophic Lateral Sclerosis (ALS) and Type 1 Diabetes. It has research and development operations in Ness Ziona, Israel.

Share on Social Networks: